panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Novartis has developed oral and intravenous formulations of panobinostat (Farydak®), a histone deacetylase (HDAC) inhibitor, for… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Panobinostat is an oral pan-deacetylase inhibitor that synergizes with bortezomib to inhibit both the aggresome and proteasome… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The polycomb repressive complex (PRC) 2 contains 3 core proteins, EZH2, SUZ12, and EED, in which the SET (suppressor of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2009
Review
2009
The deacetylase inhibitors are a structurally diverse class of targeted antineoplastic agents that have demonstrated in vitro and… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-negative myeloproliferative… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities. Herein, we report the… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?